Latex Allergy Companies | Market Research Future

Top Industry Leaders in the Latex Allergy Market

Latex Allergy Key Companies Latest Latex Allergy Companies Companies Update

July 2023: Following five years of development in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab), is now available to patients in the United States. Biocon Biologics, a company that recently made its acquisition of the global biosimilars business of Viatris, has obtained numerous biosimilar approvals in more than one hundred countries worldwide, including the United States and Europe. As a result of acquiring the biosimilars division of Viatris, Biocon Biologics is now able to assist medical professionals and patients in the treatment of diabetes, cancer, and immunology with more accessible and cost-effective options. Biocon Biologics has reached a significant milestone with the introduction of HULIO®, its biosimilar adalimumab, in the United States.

July 2023: Celltrion Healthcare, a biopharmaceutical company based in South Korea, announced on Monday that it introduced Yuflyma, a biosimilar to the autoimmune disease treatment Humira, which contains adalimumab-aaty, into the United States market the day before. Humira is a blockbuster medication, with $18.6 billion, or 87%, of its $21.2 billion in global sales in the United States last year. The treatment, which is offered in both autoinjector and prefilled hypodermic configurations, has obtained indications in the United States for eight diseases, including ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Yuflyma, a medication with a high concentration of 100 milligrams per milliliter that reduces the dosage by half compared to low-concentration alternatives, is devoid of the analgesic citrate.

List of Latex Allergy Companies Key companies in the market